A longitudinal study of anxiety and cognitive decline in dementia with Lewy bodies and Alzheimer’s disease

Monica H. Breitve¹,²,³*, Minna J. Hynninen⁴,⁵, Kolbjørn Brønnick⁶,¹², Luiza J. Chwiszczuk¹,³,⁷, Bjørn H. Auestad⁸,⁹, Dag Aarsland¹⁰,¹¹ and Arvid Rongve¹,²,³

Abstract

Background: Anxiety in dementia is common but not well studied. We studied the associations of anxiety longitudinally in Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB).

Methods: In total, 194 patients with a first-time diagnosis of dementia were included (n = 122 patients with AD, n = 72 patients with DLB). Caregivers rated the patients’ anxiety using the Neuropsychiatric Inventory, and self-reported anxiety was assessed with the anxiety and tension items on the Montgomery–Åsberg Depression Rating Scale. The Mini Mental State Examination was used to assess cognitive outcome, and the Clinical Dementia Rating (CDR)-Global and CDR boxes were used for dementia severity. Linear mixed effects models were used for longitudinal analysis.

Results: Neither in the total sample nor in AD or DLB was caregiver-rated anxiety significantly associated with cognitive decline or dementia severity over a 4-year period. However, in patients with DLB, self-reported anxiety was associated with a slower cognitive decline than in patients with AD. No support was found for patients with DLB with clinical anxiety having a faster decline than patients with DLB without clinical anxiety. Over the course of 4 years, the level of anxiety declined in DLB and increased in AD.

Conclusions: Anxiety does not seem to be an important factor for the rate of cognitive decline or dementia severity over time in patients with a first-time diagnosis of dementia. Further research into anxiety in dementia is needed.

Keywords: Alzheimer’s disease, Dementia with Lewy bodies, Dementia, Anxiety, BPSD, Longitudinal
hypothesised in previous research [7, 12]. However, others have reported that anxiety in elderly people is not associated with increased risk of dementia or cognitive decline [13, 14].

Few studies of anxiety in dementia with Lewy bodies (DLB) have been done [15]. Ricci et al. [16] found that anxiety was more common in patients with DLB than in patients with AD, and this was later supported in a study by our group [17]. Anxiety also is more common in patients with DLB than in healthy control subjects and is reported to be a risk factor for development of DLB [18]. The severity of anxiety seems to be stable across stages of dementia, except for a decrease at the terminal stage [19, 20]. In a study of early-onset AD, the severity of anxiety was increasing over 3 years, but the patients were in different dementia severity stages at baseline [21].

Anxiety has overlapping symptoms with the dementia disease itself, as well as with other behavioural and psychological symptoms (BPSD) such as agitation and depression. According to Seignourel et al. [19], there is more support for that anxiety can be seen as a separate clinical entity, and is distinctive from agitation. Depression and anxiety have a high co-morbidity rate in both healthy elderly individuals and elderly persons with dementia [17, 22]. Therefore, depression must be controlled for to establish the independent contribution of anxiety as a predictor of cognitive decline.

Identifying predictors of cognitive decline is important, especially if an early intervention could reduce the speed of cognitive decline, both in MCI and in dementia. We investigated the association between anxiety and cognitive decline during 4 years of follow-up in people with AD and individuals with DLB.

Methods

Subjects
In total, 265 outpatients in clinics of old age psychiatry and geriatric medicine in western Norway with a first-time dementia diagnosis [Mini Mental State Examination (MMSE) score >15] were recruited starting in 2005 and followed annually. Patients with acute delirium or confusion, terminal illness, or current or previous bipolar disorder or psychotic disorder, or who were recently diagnosed with a major somatic illness, were excluded [23]. Follow-up examinations were conducted at the clinic or in nursing homes. The study protocol was approved by the Regional Committee for Medical and Health Research Ethics in Western Norway. Written informed consent was obtained from all participants in this study.

Measures

Dementia diagnosis
The diagnosis of dementia was based on criteria set forth in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. AD was diagnosed according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association [24]. DLB was diagnosed according to the revised consensus criteria [25]. For further information, see the publication by Aarsland et al. [23]. Two independent raters made the diagnoses, and so far the diagnosis has been neuropathologically confirmed in 36 cases.

Assessment of anxiety and depression
Symptoms of anxiety were rated on the basis of information obtained from a caregiver using Neuropsychiatric Inventory (NPI) [26] subscale E (Anxiety). On the NPI, symptoms are assessed for the previous 30 days, rating frequency (score 1–4) and severity (score 1–3). Frequency and severity are multiplied to obtain a sum score. A score above 4 is generally seen as clinically significant [27] and was used to identify DLB cases with clinical anxiety. In the present study, both categorical (caseness, presence of clinically significant anxiety) and dimensional scores were used.

Patients’ own perceptions of anxiety were measured with the anxiety item on the Montgomery–Åsberg Depression Rating Scale (MADRS) [28]. The MADRS items are rated from 0 to 6. The anxiety item (item 3) addresses “feelings of ill-defined discomfort, edginess, inner turmoil, mental tension mounting to either panic, dread or anguish” during the previous 3 days. Ratings of the MADRS and the NPI were conducted independently.

Caregiver-rated depression was measured with NPI subscale D (Depression), and self-reported depression was measured using MADRS.

Cognitive screening and dementia severity rating
The outcome measure—progression of dementia—was measured using two scales. The MMSE [29] is a brief test used to screen for cognitive impairment. The Clinical Dementia Rating (CDR) [30] is used to assess the severity of dementia on a scale from 0 to 3 (CDR-Global). The CDR scale also comprises six cognitive and practical domains (CDR boxes): Memory, Orientation, Judgement and Problem-Solving, Community Affairs, Home and Hobbies, and Personal Care.

Statistical analyses
Statistical analyses were performed using IBM SPSS 22.0 software (IBM, Armonk, NY, USA) and the R statistical software package [31]. Differences between AD and DLB at baseline were analysed with Mann–Whitney U tests because the variables were not normally distributed, and by Pearson χ² tests for categorical data. Longitudinal analysis was done with linear mixed effects models using MMSE and CDR as dependent variables. For some
outcomes, models with both random intercept and slope were used; for others, random intercept was sufficient according to model fit criteria. For longitudinal analyses of outcomes with very few categories, the different CDR (box) scores, the assumption of a normally distributed outcome poses a problem. To overcome this, we dichotomized the CDR scores and employed mixed effects logistic regression to analyse the probability of a CDR score of 2 or greater as a function of time, anxiety, depression and possibly other covariates.

Results
Patients diagnosed with probable or possible AD \((n = 122)\) and DLB \((n = 72)\) were included in the analysis (see flowchart of study inclusion in Fig. 1). At baseline, patients with AD and patients with DLB did not differ in demographic and clinical variables, except that there were more women in the AD group and higher NPI total score in the DLB group (see Table 1).

We found no significant interaction between time and anxiety—neither caregiver-rated nor self-reported anxiety—on the MMSE, CDR-Global or CDR boxes. There was no significant interaction between diagnostic group, time and anxiety (caregiver-rated or self-reported) on the MMSE, CDR-Global or CDR boxes, except for an interaction between diagnostic group, time and MMSE for self-reported anxiety \((p = 0.039)\), even after controlling for depression and/or total MADRS score, indicating that anxiety in DLB was associated with a slower cognitive decline than in AD.

There was no significant interaction in patients with DLB between clinical significant anxiety at baseline and time on the MMSE, CDR-Global or CDR boxes.

There was a significant interaction between diagnostic group and time for caregiver-reported anxiety \((p = 0.002)\). Patients with DLB had a higher level of anxiety at baseline than patients with AD, but the anxiety level was reduced over time. This was contrary to patients with AD, among whom the level of anxiety increased over time, adjusted for CDR-Global and age (see Fig. 2). There was no significant interaction between diagnostic group and time for self-reported anxiety.

Discussion
In this longitudinal cohort study, we analysed the association of anxiety and cognition over 4 years in people with AD and individuals with DLB. We found no clear indication that anxiety was associated with a faster decline in cognition or dementia severity in either the total sample or in DLB compared with AD, or between patients with DLB with or without clinical anxiety. The only observation was that anxiety in DLB was associated with a slower cognitive decline than in AD.

The level of caregiver-reported anxiety was different between patients with AD and patients with DLB over time. During the observation period over 4 years, the level of anxiety in patients with DLB was declining,
which was the opposite of an increasing anxiety level in patients with AD. Self-reported anxiety was not found to be different over time.

The observed decline of anxiety in DLB over time could be due to treatment of anxiety-provoking hallucinations or to increased insight and learning how to interpret the hallucinations as perceptual errors so that they become pseudo-hallucinations.

Both psychological and biological mechanisms probably cause the anxiety that occurs in patients with dementia. Patients with dementia experience less coping in daily living, lose overview and control, and might fear for the future [19, 32]. In addition, atrophy and/or dysfunctions in the limbic structures may make them less capable of coping with fear and anxiety [18]. Higher levels of cortisol due to stress can also cause hippocampal atrophy [11]. Furthermore, patients with MCI and anxiety have pathological AD markers in the cerebrospinal fluid which are not found in patients with depression and MCI, which may also support a role of biological mechanisms [33].

Even though we did not find that anxiety was associated with the rate of cognitive decline or dementia severity, it is important to focus on anxiety to avoid negative consequences for patients and their caregivers, as mentioned above. In dementia care, anxiety should be screened for and, when required, thoroughly mapped before intervention.

Some limitations of our study should be noted. We used NPI as the main anxiety measure, which is an indirect way to measure anxiety via relatives or nursing home personnel. This is a commonly used and validated measure in dementia research, but it may not have satisfactory psychometric properties for measuring anxiety [19]. In factor analysis of NPI, anxiety and depression often load on the same factor. A majority of the studies have included only patients with AD, and we found few published studies that included patients with DLB or analysed them as a subgroup [34, 35]. In our study, the correlations between anxiety and other subtests from the NPI at baseline were low, both in the total sample and in AD and DLB, but in the longitudinal analysis we controlled for depression to ensure that an observed effect from anxiety was not due to a BPSD subsyndrome.

It has been recommended that, when studying anxiety in people with dementia, information should be collected from multiple sources because the caregivers can report verbalized or behavioural signs of anxiety but not the internalized symptoms [19]. We therefore used one item on MADRS to measure self-reported anxiety, and it is based on the reliability of the patients’ answer. Bradford et al. [36] suggested that people with mild to moderate dementia can give reliable self-reports of anxiety symptoms, with validity comparable to reports obtained from caregivers. In our sample, after 4 years, 34 % had a CDR score of 3, which indicates severe

### Table 1

| Characteristics | Total (n = 194) | AD (n = 122) | DLB (n = 72) | p Value* |
|----------------|----------------|-------------|-------------|----------|
| Age, yr (SD)   | 75.8 (7.6)     | 75.7 (7.8)  | 76.0 (7.3)  | 0.951    |
| Women, n (%)   | 122 (62.9)     | 90 (73.6)   | 32 (44.4)   | <0.001   |
| Education, yr (SD) | 9.6 (2.9)     | 9.6 (3.0)   | 9.6 (2.9)   | 0.851    |
| MMSE, mean (SD) | 23.5 (2.7)     | 23.6 (2.3)  | 23.3 (3.1)  | 0.693    |
| CDR-Global, median (IQR) | 1.0 (0.5)     | 1.0 (0.5)   | 1.0 (0.5)   | 0.071    |
| NPI anxiety, mean (SD) | 1.8 (3.0)     | 1.5 (2.7)   | 2.2 (3.6)   | 0.197    |
| NPI depression, mean (SD) | 2.0 (2.6)     | 1.9 (2.5)   | 2.4 (2.7)   | 0.147    |
| NPI total, mean (SD) | 18.5 (17.3)   | 15.6 (16.0) | 23.7 (18.2) | 0.001    |
| MADRS anxiety, median (IQR) | 0 (2)         | 0 (2)       | 1 (2)       | 0.109    |
| Clinically significant anxiety, % (median/IQR) | 19.9          | 18.6 (6/4)  | 22.1 (8/8)  | 0.237    |
| Non–clinically significant anxiety, % (median/IQR) | 80.1          | 81.4 (0/0)  | 77.9 (0/1)  | 0.204    |

**Abbreviations:** AD Alzheimer’s disease, DLB Dementia with Lewy bodies, MMSE Mini Mental State Examination, CDR Clinical Dementia Rating, IQR interquartile range, NPI Neuropsychiatric Inventory, MADRS Montgomery–Åsberg Depression Rating Scale, SD standard deviation

* Differences between the AD and DLB groups were analysed using the Mann-Whitney U test and Pearson’s χ² test.
dementia and can challenge the reliability of the score. In addition, assessing anxiety with only one item from a depression scale is not optimal and limits the reliability of the findings. Observations based only on this score which are not in accordance with established research should therefore be carefully weighed.

The MMSE and the CDR scale were used as outcome measures. MMSE has been criticized for not being able to adequately monitor cognitive decline in pure DLB [37]. However, the MMSE was found to be sensitive for cognitive changes in Parkinson’s disease, which shares many features with DLB [38]. CDR is designed for the phenotypes of AD, and less is known about the psychometric properties when addressing DLB.

There were also missing data in our analysis, due both to the inevitable facts that the dementia was progressing and the patients were not able to participate in the assessments, and also because of natural mortality during follow-up. The most appropriate analysis, linear mixed effects, was used to minimize this problem. There is still a possibility that the null hypothesis was supported because of inadequate power. Unfortunately, the dataset was not large enough to perform joint analysis.

The strengths of our study are that it include a relatively large number of patients with DLB and that they were followed annually until death. Patients were included in the study according to the latest DLB consortium criteria; they were thoroughly evaluated at baseline; some also underwent ioflupane single-photon emission computed tomography; and the diagnosis of the patients was revised after 2 and 5 years by an expert panel. Post-mortem autopsies of 36 patients to date have confirmed the clinical diagnosis, with the exception of two false-positive cases and one false-negative case for DLB.

Conclusions
In this study, anxiety was not associated with the dementia progression rate in AD or DLB. Anxiety gradually decreased over 4 years in DLB but gradually increased in AD. More studies are needed.

Abbreviations
AD: Alzheimer’s disease; BPSD: behavioural and psychological symptoms; CDR: Clinical Dementia Rating; DemVest: Dementia Study of Western Norway; DLB: dementia with Lewy bodies; FTD: frontotemporal dementia; IQR: interquartile range; MADRS: Montgomery-Åsberg Depression Rating Scale; MCI: mild cognitive impairment; MMSE: Mini Mental State Examination; NPI: Neuropsychiatric Inventory; PDD: Parkinson disease dementia; SD: Standard deviation; VaD: vascular dementia.

Competing interests
DA has received research support and honoraria from H. Lundbeck, Novartis Pharmaceuticals and GE Healthcare Life Sciences. The other authors declare that they have no competing interests.

Authors’ contributions
MHB participated in the data acquisition, made the hypothesis, analysed and interpreted data and drafted the manuscript. MUH made the hypothesis, analysed and interpreted data, and drafted the manuscript. BHA performed longitudinal analysis, interpreted the results, wrote part of the statistical analysis and revised the manuscript. KB, LJC, DA and AR contributed to the hypothesis and interpretation of the analysis and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We thank the patients and their caregivers for participating in the study.

Author details
1Department of Research and Innovation, Helse-Fonna HF Haugesund Hospital, Postbox 2170, 5504 Haugesund, Norway. 2Old Age Department, Clinic of Psychiatry, Helse-Fonna HF Haugesund Hospital, Postbox 2170, 5504 Haugesund, Norway. 3Faculty of Medicine, University of Bergen, Postbox 7804, 5020 Bergen, Norway. 4Department of Clinical Psychology, University of Bergen, Christie Gate 12, 5015 Bergen, Norway. 5NKS Olaviken Psychogeriatric Hospital, Ulviksalen 8, 5009 Bergen, Norway. 6TIPS – Centre for Clinical Research in Psychosis, Stavanger University Hospital, 4011 Stavanger, Norway. 7Neurological Department, Clinic of Medicine, Helse-Fonna HF Haugesund Hospital, Postbox 2170, 5504 Haugesund, Norway. 8Research Department, Stavanger University Hospital, Stavanger, Norway. 9Department of Mathematics and Natural Sciences, University of Stavanger, 4011 Stavanger, Norway. 10Centre for Age-Related Medicine, Stavanger University Hospital, Armauer Hansens vei 20, 4011 Stavanger, Norway. 11Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Centre for Alzheimer Research, Karolinska Institutet, 141 57 Huddinge, Sweden. 12Network for Medical Sciences, University of Stavanger, 4036 Stavanger, Norway.

Received: 7 September 2015 Accepted: 3 December 2015
Published online: 26 January 2016

References
1. Mintzer JE, Brawman-Mintzer O, Mirski DF, Barkin K. Anxiety in the behavioral and psychological symptoms of dementia. Int Psychogeriatr. 1999;12 Suppl 51:339–42.
2. Teri L, Ferretti LE, Gibbons LE, Logsdon RG, McCurry SM, Kukull WA, et al. Anxiety in Alzheimer’s disease: prevalence and comorbidity. J Gerontol A Biol Sci Med Sci. 1999;54:M348–52.
3. Gibbons LE, Teri L, Logsdon RG, McCurry SM, Kukull W, Bowen J, et al. Anxiety symptoms as predictors of nursing home placement in patients with Alzheimer’s disease. J Clin Geropsychol. 2002;8:335–42.
4. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Assessing quality of life in older adults with cognitive impairment. Psychosom Med. 2002;64:510–9.
5. Haupt M, Karger A, Jänner M. Improvement of agitation and anxiety in demented patients after psychoeducative group intervention with their caregivers. Int J Geriatr Psychiatry. 2000;15:1125–9.
6. KaufeDi, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer’s disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46:210–5.
7. Sinoff G, Werner P. Anxiety disorder and accompanying subjective memory loss in the elderly as a predictor of future cognitive decline. Int J Geriatr Psychiatry. 2003;18:951–9.
8. Banks SJ, Raman R, He F, Salmon DP, Ferris S, Aisen P, et al. The Alzheimer’s Disease Cooperative Study Prevention Instrument Project: longitudinal outcome of behavioral measures as predictors of cognitive decline. Dement Geriatr Cogn Dis Extra. 2014;4:509–16.
9. Beaudreau SA, O’Hara R. Late-life anxiety and cognitive impairment: a review. Am J Geriatr Psychiatry. 2008;16:790–803.
10. Palmer K, Berger AK, Monastero R, Winblad B, Backman L, Fratiglioni L. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology. 2007;68:1506–602.
11. Mah L, Binns MA, Steffens DC, Alzheimer’s Disease Neuroimaging Initiative. Anxiety symptoms in amnestic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease. Am J Geriatr Psychiatry. 2015;23:466–76.
12. Burton C, Campbell P, Jordan K, Strauss V, Mallen C. The association of anxiety and depression with future dementia diagnosis: a case-control study in primary care. Fam Pract. 2013;30:25–30.
13. Bierman EM, Cornish HC, Jonker C, Scheltens P, Beekman ATF. The effect of anxiety and depression on decline of memory function in Alzheimer's disease. Int Psychogeriatr. 2009;21:1142–7.
14. de Bruin RFAQ, Direk N, Mizra SS, Hofman A, Koudstaal PJ, Tiemeier H, et al. Anxity is not associated with the risk of dementia or cognitive decline: the Rotterdam Study. Am J Geriatr Psychiatry. 2014;22:1382–90.
15. Borroni B, Agosti C, Padovani A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatr. 2008;46:101–6.
16. Ricci M, Guidoni SV, Sepe-Monti M, Bombsci G, Antonini G, Blundo C, et al. Clinical findings, functional abilities and caregiver distress in the early stage of dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Arch Gerontol Geriatr. 2009;49:e101–4.
17. Hynninen MJ, Breitve MH, Rongve A, Aarsland D, Nordhus IH. The frequency and correlates of anxiety in patients with first-time diagnosed mild dementia. Int Psychogeriatr. 2012;24:1771–8.
18. Boot BP, Orr CF, Ahlskog JE, Ferman TJ, Roberts R, Pankratz V, et al. Risk factors for dementia with Lewy bodies: a case-control study. Neurology. 2013;81:1833–40.
19. Seignourel PJ, Kunik ME, Snow L, Wilson N, Stanley M. Anxiety in dementia: a critical review. Clin Psychol Rev. 2008;28:1071–82.
20. Tanaka H, Hashimoto M, Fukushima R, Ishikawa T, Yatabe Y, Kaneda K, et al. Relationship between dementia severity and behavioural and psychological symptoms in early-onset Alzheimer's disease. Psychogeriatrics. 2015;15:242–7.
21. Brodaty H, Connors MH, Xu J, Woodward M, Ames D, PRIME study group. The course of neuropsychiatric symptoms in dementia: a 3-year longitudinal study. J Am Med Dir Assoc. 2015;16:380–7.
22. Biringer E, Nykänen A, Dahl AA, Smith AD, Engedal K, Ngaard HA, et al. The association between depression, anxiety, and cognitive function in the elderly general population – the Hordaland Health Study. Int J Geriatr Psychiatry. 2005;20:989–97.
23. Aarsland D, Rongve A, Pienaarstok Nore S, Skogseth R, Skullstad S, Ehtu U, et al. Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord. 2008;26:445–52.
24. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB). Report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006;9:417–23.
25. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–14.
26. Porter VR, Buxton WG, Fairbanks LA, Strickland T, O'Connor SM, Rosenberg-Thompson S, et al. Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias. J Neuropsychiatry Clin Neurosci. 2003;15:180–6.
27. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.
28. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
29. Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr. 1999;9:173–8.
30. The R Project for Statistical Computing. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. https://www.r-project.org/. Accessed 17 January 2016.
31. James I. Using a cognitive rationale to conceptualize anxiety in people with dementia. Behav Cogn Psychother. 1999;27:345–51.
32. Morris KS, Verhey FR, Scheltens P, Hampel H, Soininen H, Aalten P, et al. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med. 2013;43:911–20.
33. Lai CK. The merits and problems of Neuropsychiatric Inventory as an assessment tool in people with dementia and other neurological disorders. Clin Interv Aging. 2014;9:1051–61.
34. Aalten P, Verhey FR, Boziki M, Brugnolo A, Bullock R, Byrne EJ, et al. Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Dement Geriatr Cogn Disord. 2008;25:1–8.
35. Bradford A, Breen GA, Robinson RA, Wilson N, Snow AL, Kunik ME, et al. Concordance of self- and proxy-rated worry and anxiety symptoms in older adults with dementia. J Anxiety Disord. 2013;27:125–30.
36. Nelson PT, Kryscio RJ, Jicha GA, Abner EL, Schmitt FA, Xu LO, et al. Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology. 2009;73:127–33.
37. Lessig S, Nie D, Xu R, Corey-Bloom J. Changes on brief cognitive instruments over time in Parkinson’s disease. Mov Disord. 2012;27:1125–8.